
    
      Besides the main objectives, there are other objectives as follows:

        1. To evaluate efficacy of ALS-L1023 for liver fibrosis and steatosis by noninvasive
           imaging biomarker MRI-PDFF and MRE

        2. To determine optimized dose of ALS-L1023 in NASH disease
    
  